Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

204 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Variation in mutation spectrum partly explains regional differences in the breast cancer risk of female BRCA mutation carriers in the Netherlands.
Vos JR, Teixeira N, van der Kolk DM, Mourits MJ, Rookus MA, van Leeuwen FE, Collée M, van Asperen CJ, Mensenkamp AR, Ausems MG, van Os TA, Meijers-Heijboer HE, Gómez-Garcia EB, Vasen HF, Brohet RM; Hereditary Breast and Ovarian Cancer Research Group Netherlands; van der Hout AH, Jansen L, Oosterwijk JC, de Bock GH. Vos JR, et al. Among authors: mourits mj. Cancer Epidemiol Biomarkers Prev. 2014 Nov;23(11):2482-91. doi: 10.1158/1055-9965.EPI-13-1279. Epub 2014 Aug 7. Cancer Epidemiol Biomarkers Prev. 2014. PMID: 25103822
Quality-of-life effects of prophylactic salpingo-oophorectomy versus gynecologic screening among women at increased risk of hereditary ovarian cancer.
Madalinska JB, Hollenstein J, Bleiker E, van Beurden M, Valdimarsdottir HB, Massuger LF, Gaarenstroom KN, Mourits MJ, Verheijen RH, van Dorst EB, van der Putten H, van der Velden K, Boonstra H, Aaronson NK. Madalinska JB, et al. Among authors: mourits mj. J Clin Oncol. 2005 Oct 1;23(28):6890-8. doi: 10.1200/JCO.2005.02.626. Epub 2005 Aug 29. J Clin Oncol. 2005. PMID: 16129845 Free article.
Predictors of prophylactic bilateral salpingo-oophorectomy compared with gynecologic screening use in BRCA1/2 mutation carriers.
Madalinska JB, van Beurden M, Bleiker EM, Valdimarsdottir HB, Lubsen-Brandsma L, Massuger LF, Mourits MJ, Gaarenstroom KN, van Dorst EB, van der Putten H, Boonstra H, Aaronson NK. Madalinska JB, et al. Among authors: mourits mj. J Clin Oncol. 2007 Jan 20;25(3):301-7. doi: 10.1200/JCO.2006.07.4922. J Clin Oncol. 2007. PMID: 17235045
One risk fits all?
De Bock GH, Mourits MJ, Oosterwijk JC. De Bock GH, et al. Among authors: mourits mj. J Clin Oncol. 2007 Aug 1;25(22):3383-4; author reply 3384. doi: 10.1200/JCO.2007.12.3489. J Clin Oncol. 2007. PMID: 17664491 No abstract available.
Prospective study of long-term impact of adjuvant high-dose and conventional-dose chemotherapy on health-related quality of life.
Buijs C, Rodenhuis S, Seynaeve CM, van Hoesel QG, van der Wall E, Smit WJ, Nooij MA, Voest E, Hupperets P, TenVergert EM, van Tinteren H, Willemse PH, Mourits MJ, Aaronson NK, Post WJ, de Vries EG. Buijs C, et al. Among authors: mourits mj. J Clin Oncol. 2007 Dec 1;25(34):5403-9. doi: 10.1200/JCO.2007.11.2813. J Clin Oncol. 2007. PMID: 18048822 Free article. Clinical Trial.
Prognosis of uterine corpus cancer after tamoxifen treatment for breast cancer.
Hoogendoorn WE, Hollema H, van Boven HH, Bergman E, de Leeuw-Mantel G, Platteel I, Fles R, Nederlof PM, Mourits MJ, van Leeuwen FE; Comprehensive Cancer Centers TAMARISK-group. Hoogendoorn WE, et al. Among authors: mourits mj. Breast Cancer Res Treat. 2008 Nov;112(1):99-108. doi: 10.1007/s10549-007-9823-1. Epub 2007 Dec 7. Breast Cancer Res Treat. 2008. PMID: 18064567
Time to stop ovarian cancer screening in BRCA1/2 mutation carriers?
van der Velde NM, Mourits MJ, Arts HJ, de Vries J, Leegte BK, Dijkhuis G, Oosterwijk JC, de Bock GH. van der Velde NM, et al. Among authors: mourits mj. Int J Cancer. 2009 Feb 15;124(4):919-23. doi: 10.1002/ijc.24038. Int J Cancer. 2009. PMID: 19035463 Free article.
204 results